WHO Warns Against Three India-Made Cough Syrups After Child Deaths
The World Health Organization issued a global alert over three contaminated cough syrups made in India, the latest development in a series of quality-control failures linked to the deaths of more than a dozen children.
The tainted products were found in specific batches of COLDRIF, Respifresh TR and ReLife manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals and Shape Pharma, the WHO said in a notification late Monday. These were used to treat cough, flu and common cold.
At least 22 children have died in the central Indian state of Madhya Pradesh, local media reports say. India's health regulator, Central Drugs Standard Control Organization, found diethylene glycol in these three cough syrups — a toxic substance that's also showed up in other some tainted products made in India over the last few years.
While the Indian drug regulator has confirmed that the contaminated medicines have not been exported and there's no evidence so far of illegal trade, the global health agency urged public health authorities to ramp up scrutiny and report back immediately if these products are detected in their countries.
Gambia Deaths
While India has become the world's largest supplier of cheap non-patented medicines, it has also struggled to police the manufacturing standards, especially in thousands of smaller drug makers.
More than 60 children in Gambia died in 2022, after consuming cough syrup from India. A year later, more than a dozen cases of blindness in the US were linked to contaminated eye drops.
WHO asked public health authorities on Monday “to consider targeted market surveillance, with particular attention to informal and unregulated supply chains” where three cough medicines may circulate undetected. It also urged them to “carefully evaluate” any oral medicines from these manufacturing sites, especially those produced since December.
Indian authorities have started a criminal investigation into the manufacturer, according to India's Ministry of Health and Family Welfare.
The state government of Tamil Nadu, where the manufacturer Sresan Pharmaceutical is based, has revoked the license of the manufacturer, the Press Trust of India said in a recent report.
Production Halt
The Indian drug regulator has confirmed that states have ordered an immediate halt to its production and have suspended product authorizations as well as issued a recall of the tainted medicines.
The Indian regulator has also sought stricter testing of ingredients for drugs, it said in a circular last week, and asked all regional bodies to ensure raw materials and finished formulations are tested before those are released to the market.
The WHO continues to work closely with Indian health authorities to monitor the situation, identify the source of the contamination and mitigate any potential public health risks, it said in the alert.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.